Affini-T Therapeutics

Affini-T Therapeutics is a biotechnology company focused on developing TCR-based immunotherapies for the treatment of solid tumors. Utilizing two complementary therapeutic modalities, the company targets oncogenic driver mutations such as TP53 R175H and KRAS G12D/G12V. Affini-T Therapeutics is committed to advancing its pipeline programs to combat cancer and improve patient outcomes through innovative science and research.